Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases
Gespeichert in:
| Veröffentlicht in: | Clinical lung cancer 2019-05, Vol.20 (3), p.e247-e250 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e250 |
|---|---|
| container_issue | 3 |
| container_start_page | e247 |
| container_title | Clinical lung cancer |
| container_volume | 20 |
| creator | Schwarz, Michael Kocher, Florian Niedersuess-Beke, Dora Rudzki, Jakob Hochmair, Maximilian Widmann, Gerlig Hilbe, Wolfgang Pircher, Andreas |
| description | |
| doi_str_mv | 10.1016/j.cllc.2018.12.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179369608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525730418303309</els_id><sourcerecordid>2179369608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-c2515dcb80cac1ccdaed162e454a4fe79cdb0d8e3c45d4ae86fa16bb3f588c113</originalsourceid><addsrcrecordid>eNp9kU2O1DAQhSMEYn7gAiyQlz2LBNtJ3AliM4r4mVFraMGwtpxyBdwkdrCTEb2bO3AHDsZJcOiGJQvL1qtXT1X-kuQZoxmjTLzYZdD3kHHKqozxjFLxIDlldV6lVNT0YXyXvEzXOS1OkrMQdpRykTP-ODnJqchjrTpNfl4Nw2xdmMfRYwjGWdI5T_6oSJovCF9HZ-yUeuzVhJrcuu8GzLQnjbLxzAHJ1uI8ONiHyQRybby7QzDmKFujyGp7vb0gxpIbZ3_d_wiD6vsUsO_JZraflyRAT1Y3H5tNc_GSXJIPODo_EdcRHqsBw5PkUaf6gE-P93ny6c3r2-Zdunn_9qq53KRQcD6lwEtWamgrCgoYgFaomeBYlIUqOlzXoFuqK8yhKHWhsBKdYqJt866sKmAsP09Wh9zRu28zhkkOJiyTKotuDpKzdZ2LWtAqWvnBCt6F4LGTozeD8nvJqFz4yJ1c-MiFj2RcRj6x6fkxf24H1P9a_gKJhlcHA8Yt7wx6GcBg_B9tPMIktTP_y_8NgcOkRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2179369608</pqid></control><display><type>article</type><title>Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Schwarz, Michael ; Kocher, Florian ; Niedersuess-Beke, Dora ; Rudzki, Jakob ; Hochmair, Maximilian ; Widmann, Gerlig ; Hilbe, Wolfgang ; Pircher, Andreas</creator><creatorcontrib>Schwarz, Michael ; Kocher, Florian ; Niedersuess-Beke, Dora ; Rudzki, Jakob ; Hochmair, Maximilian ; Widmann, Gerlig ; Hilbe, Wolfgang ; Pircher, Andreas</creatorcontrib><identifier>ISSN: 1525-7304</identifier><identifier>EISSN: 1938-0690</identifier><identifier>DOI: 10.1016/j.cllc.2018.12.006</identifier><identifier>PMID: 30635258</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma, Non-Small-Cell Lung - complications ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Case report ; Checkpoint inhibitors ; Drug Resistance, Neoplasm ; Drug-Related Side Effects and Adverse Reactions - diagnosis ; Fatal Outcome ; Glucocorticoids ; Humans ; Immune checkpoint blockade ; Immunotherapy - adverse effects ; Immunotherapy - methods ; Lung Neoplasms - complications ; Lung Neoplasms - drug therapy ; Male ; Nivolumab - adverse effects ; Nivolumab - therapeutic use ; Pneumocystis carinii - physiology ; Pneumonia, Pneumocystis - diagnosis ; Pneumonia, Pneumocystis - etiology ; Pneumonitis ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Respiratory Insufficiency - diagnosis</subject><ispartof>Clinical lung cancer, 2019-05, Vol.20 (3), p.e247-e250</ispartof><rights>2018 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-c2515dcb80cac1ccdaed162e454a4fe79cdb0d8e3c45d4ae86fa16bb3f588c113</citedby><cites>FETCH-LOGICAL-c422t-c2515dcb80cac1ccdaed162e454a4fe79cdb0d8e3c45d4ae86fa16bb3f588c113</cites><orcidid>0000-0001-7963-3385 ; 0000-0002-2587-1385</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1525730418303309$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30635258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schwarz, Michael</creatorcontrib><creatorcontrib>Kocher, Florian</creatorcontrib><creatorcontrib>Niedersuess-Beke, Dora</creatorcontrib><creatorcontrib>Rudzki, Jakob</creatorcontrib><creatorcontrib>Hochmair, Maximilian</creatorcontrib><creatorcontrib>Widmann, Gerlig</creatorcontrib><creatorcontrib>Hilbe, Wolfgang</creatorcontrib><creatorcontrib>Pircher, Andreas</creatorcontrib><title>Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases</title><title>Clinical lung cancer</title><addtitle>Clin Lung Cancer</addtitle><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - complications</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Case report</subject><subject>Checkpoint inhibitors</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug-Related Side Effects and Adverse Reactions - diagnosis</subject><subject>Fatal Outcome</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Immune checkpoint blockade</subject><subject>Immunotherapy - adverse effects</subject><subject>Immunotherapy - methods</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Nivolumab - adverse effects</subject><subject>Nivolumab - therapeutic use</subject><subject>Pneumocystis carinii - physiology</subject><subject>Pneumonia, Pneumocystis - diagnosis</subject><subject>Pneumonia, Pneumocystis - etiology</subject><subject>Pneumonitis</subject><subject>Programmed Cell Death 1 Receptor - antagonists & inhibitors</subject><subject>Respiratory Insufficiency - diagnosis</subject><issn>1525-7304</issn><issn>1938-0690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2O1DAQhSMEYn7gAiyQlz2LBNtJ3AliM4r4mVFraMGwtpxyBdwkdrCTEb2bO3AHDsZJcOiGJQvL1qtXT1X-kuQZoxmjTLzYZdD3kHHKqozxjFLxIDlldV6lVNT0YXyXvEzXOS1OkrMQdpRykTP-ODnJqchjrTpNfl4Nw2xdmMfRYwjGWdI5T_6oSJovCF9HZ-yUeuzVhJrcuu8GzLQnjbLxzAHJ1uI8ONiHyQRybby7QzDmKFujyGp7vb0gxpIbZ3_d_wiD6vsUsO_JZraflyRAT1Y3H5tNc_GSXJIPODo_EdcRHqsBw5PkUaf6gE-P93ny6c3r2-Zdunn_9qq53KRQcD6lwEtWamgrCgoYgFaomeBYlIUqOlzXoFuqK8yhKHWhsBKdYqJt866sKmAsP09Wh9zRu28zhkkOJiyTKotuDpKzdZ2LWtAqWvnBCt6F4LGTozeD8nvJqFz4yJ1c-MiFj2RcRj6x6fkxf24H1P9a_gKJhlcHA8Yt7wx6GcBg_B9tPMIktTP_y_8NgcOkRg</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Schwarz, Michael</creator><creator>Kocher, Florian</creator><creator>Niedersuess-Beke, Dora</creator><creator>Rudzki, Jakob</creator><creator>Hochmair, Maximilian</creator><creator>Widmann, Gerlig</creator><creator>Hilbe, Wolfgang</creator><creator>Pircher, Andreas</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7963-3385</orcidid><orcidid>https://orcid.org/0000-0002-2587-1385</orcidid></search><sort><creationdate>201905</creationdate><title>Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases</title><author>Schwarz, Michael ; Kocher, Florian ; Niedersuess-Beke, Dora ; Rudzki, Jakob ; Hochmair, Maximilian ; Widmann, Gerlig ; Hilbe, Wolfgang ; Pircher, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-c2515dcb80cac1ccdaed162e454a4fe79cdb0d8e3c45d4ae86fa16bb3f588c113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - complications</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Case report</topic><topic>Checkpoint inhibitors</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug-Related Side Effects and Adverse Reactions - diagnosis</topic><topic>Fatal Outcome</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Immune checkpoint blockade</topic><topic>Immunotherapy - adverse effects</topic><topic>Immunotherapy - methods</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Nivolumab - adverse effects</topic><topic>Nivolumab - therapeutic use</topic><topic>Pneumocystis carinii - physiology</topic><topic>Pneumonia, Pneumocystis - diagnosis</topic><topic>Pneumonia, Pneumocystis - etiology</topic><topic>Pneumonitis</topic><topic>Programmed Cell Death 1 Receptor - antagonists & inhibitors</topic><topic>Respiratory Insufficiency - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schwarz, Michael</creatorcontrib><creatorcontrib>Kocher, Florian</creatorcontrib><creatorcontrib>Niedersuess-Beke, Dora</creatorcontrib><creatorcontrib>Rudzki, Jakob</creatorcontrib><creatorcontrib>Hochmair, Maximilian</creatorcontrib><creatorcontrib>Widmann, Gerlig</creatorcontrib><creatorcontrib>Hilbe, Wolfgang</creatorcontrib><creatorcontrib>Pircher, Andreas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lung cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schwarz, Michael</au><au>Kocher, Florian</au><au>Niedersuess-Beke, Dora</au><au>Rudzki, Jakob</au><au>Hochmair, Maximilian</au><au>Widmann, Gerlig</au><au>Hilbe, Wolfgang</au><au>Pircher, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases</atitle><jtitle>Clinical lung cancer</jtitle><addtitle>Clin Lung Cancer</addtitle><date>2019-05</date><risdate>2019</risdate><volume>20</volume><issue>3</issue><spage>e247</spage><epage>e250</epage><pages>e247-e250</pages><issn>1525-7304</issn><eissn>1938-0690</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30635258</pmid><doi>10.1016/j.cllc.2018.12.006</doi><orcidid>https://orcid.org/0000-0001-7963-3385</orcidid><orcidid>https://orcid.org/0000-0002-2587-1385</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-7304 |
| ispartof | Clinical lung cancer, 2019-05, Vol.20 (3), p.e247-e250 |
| issn | 1525-7304 1938-0690 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179369608 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Case report Checkpoint inhibitors Drug Resistance, Neoplasm Drug-Related Side Effects and Adverse Reactions - diagnosis Fatal Outcome Glucocorticoids Humans Immune checkpoint blockade Immunotherapy - adverse effects Immunotherapy - methods Lung Neoplasms - complications Lung Neoplasms - drug therapy Male Nivolumab - adverse effects Nivolumab - therapeutic use Pneumocystis carinii - physiology Pneumonia, Pneumocystis - diagnosis Pneumonia, Pneumocystis - etiology Pneumonitis Programmed Cell Death 1 Receptor - antagonists & inhibitors Respiratory Insufficiency - diagnosis |
| title | Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A16%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunosuppression%20for%20Immune%20Checkpoint-related%20Toxicity%20Can%20Cause%20Pneumocystis%20Jirovecii%20Pneumonia%20(PJP)%20in%20Non%E2%80%93small-cell%20Lung%20Cancer%20(NSCLC):%20A%20Report%20of%202%20Cases&rft.jtitle=Clinical%20lung%20cancer&rft.au=Schwarz,%20Michael&rft.date=2019-05&rft.volume=20&rft.issue=3&rft.spage=e247&rft.epage=e250&rft.pages=e247-e250&rft.issn=1525-7304&rft.eissn=1938-0690&rft_id=info:doi/10.1016/j.cllc.2018.12.006&rft_dat=%3Cproquest_cross%3E2179369608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2179369608&rft_id=info:pmid/30635258&rft_els_id=S1525730418303309&rfr_iscdi=true |